Keywords: NicOx, GlaxoSmithKline, FDA, Naproxcinod, Osteoporosis, Promacta, Thrombocytopenia, FDA

Disappointments for NicOx, as FDA panel rejects naproxcinod, and GlaxoSmithKline, which halts Promacta trial

Article | 13 May 2010

Print This

US Food and Drug Administration news impacted negatively on French biotechnology firm NicOx, causing a setback for its osteoarthritis drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in